Common Warts Market Insights, Epidemiology and Market Forecasts, 2032 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Common Warts – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.

This “Common Warts- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Common Warts Epidemiology

The Common Warts epidemiology division provide insights about historical and current Common Warts patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Common Warts epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Common Warts Epidemiology

The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Common Warts Drug Chapters

Drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Common Warts clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Common Warts treatment.

Common Warts Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Common Warts treatment.

Common Warts Market Outlook

The Common Warts market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Common Warts market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Common Warts market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Common Warts Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched in the market during the study period 2019-2032. The analysis covers Common Warts market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Common Warts Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Common Warts key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Common Warts emerging therapies.

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Common Warts Market Overview at a Glance

3.1 Market Share (%) Distribution of Common Warts in 2019

3.2 Market Share (%) Distribution of Common Warts in 2032

4 Executive Summary of Common Warts

5 Disease Background and Overview

5.1 Introduction

5.2 Signs and Symptoms

5.3 Etiology

5.4 Classification

5.5 Risk Factors

5.6 Histopathology

5.7 Pathophysiology

5.8 Diagnosis

5.9 Differential diagnosis of verruca vulgaris pathology

6 Management and Treatment

6.1 Diagnostic and Treatment Guidelines

6.1.1 British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 7MM Total Prevalent Patient Population of Common Warts

7.3 Assumptions and Rationales

7.4 The United States

7.4.1 Diagnosed prevalent cases of Common warts in the United States

7.4.2 Gender specific Prevalence of Common Warts in the United States

7.5 EU-5

7.5.1 Diagnosed Prevalent Cases of Common Warts in EU-5

7.5.2 Gender specific Prevalence of Common Warts in EU-5

7.6 Japan

7.6.1 Diagnosed Prevalent cases of Common warts in Japan

7.6.2 Gender specific Prevalence of Common Warts in Japan

8 Patient Journey 1

9 Patient Journey 2

10 Emerging Therapies

10.1 Candin: Nielsen BioSciences

10.1.1 Drug Description

10.1.2 Product Development

10.1.3 Clinical Development

10.1.4 Safety and Efficacy

10.1.5 Clinical Trials Information

10.1.6 Product Profile

10.2 VBP-245: Veloce BioPharma

10.2.1 Drug Description

10.2.2 Clinical Development

10.2.3 Safety and Efficacy

10.2.4 Clinical Trials Information

10.2.5 Product Profile

10.3 VP-102: Verrica Pharmaceutical

10.3.1 Drug Description

10.3.2 Product Development

10.3.3 Clinical Development

10.3.4 Safety and Efficacy

10.3.5 Clinical Trials Information

10.3.6 Product Profile

10.4 CLS006: Maruho Co., Ltd.

10.4.1 Product Description

10.4.2 Other Developmental Activities

10.4.3 Clinical Development

10.4.4 Clinical Trials Information

10.4.5 Product Profile

10.5 A-101: Aclaris Therapeutics, Inc.

10.5.4 Product Description

10.5.2 Clinical Development

10.5.3 Clinical Trials Information

10.5.5 Product Profile

11 Current Marketed Therapies: Generics

11.1 Salicylic acid

11.2 Bleomycin

11.3 5-Fluorouracil

11.4 Cimetidine

11.5 Imiquimod

12 Other Topical Agents

12.1 Cantharidin

12.2 Retinoids

12.3 Zinc

13 Common Warts: 7 Major Market Analysis

13.1 Key Findings

13.2 Market Size of Common Warts in 7MM

13.3 Market Size of Common Warts by Therapies

14 Market Outlook

14.1 United States Market Size

14.1.1 Total Market Size of Common warts in the United States

14.1.2 Market Size of Common Warts by Therapies in United States

14.2 EU-5 Market Size

14.2.1 Total Market Size of Common warts in EU-5

14.2.2 Market Size of Common Warts by Therapies in EU-5

14.3 Japan

14.3.1 Total Market size of Common Warts in Japan

14.3.2 Market Size of Common Warts by Therapies in Japan

15 KOL Views

16 Unmet Needs

17 SWOT Analysis

18 Appendix

Companies Mentioned

• Nielsen BioSciences
• Veloce BioPharma
• Verrica Pharmaceutical
• Maruho Co., Ltd
• Aclaris Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/glposs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900